Business Wire

Dave Powell’s “Vintage of the Century” to Be Sold via NFT

18.10.2021 22:00:00 EEST | Business Wire | Press release

Share

Celebrated winemaker Dave Powell will be the first vintner ever to sell an entire vintage by NFT, when he puts his 2021 single-vineyard vintage wines under the hammer on OpenSea, under his new brand Neldner Road.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005327/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Barrels of Neldner Road single-vineyard wines, which are being offered as individual NFTs on OpenSea. Visit www.neldnerroad.com.au. (Photo: Business Wire)

Powell, founder of Torbreck and more recently Powell & Son, said the decision to sell the vintage this way made sense.

“I’ve always liked to try new things and when I found out about NFTs, it seemed to fit,” he said. “This reminds me of how wines are sold in Bordeaux through their en primeur system. Like the more ‘traditional’ NFT products, our wine is rare – just 100 barrels; it’s unique – every vintage is different; and it’s the original collectible – the oldest personal wine collection dates back nearly 4,000 years.”

Powell has emulated ultra-luxury wine auctions like the Napa Wine Auction, and included within the NFTs one-of-a-kind experiences, such as:

  • Working a day’s vintage with Dave and his crew plus dinner together
  • The barrel bottled into personalised wine bottles
  • Wine cellared by Neldner Road
  • Barrel head with personalised plaque

Some barrels come with a hologram of the barrel, and there are exclusive travel and hospitality experiences with Dave for buyers who buy multiple NFTs or the entire vintage (details here).

Powell rebranded his internationally renowned wines as Neldner Road this year, in recognition of the “sense of place” that is the heart of his life’s work.

“These vineyards are some of the oldest in the world – older than the famous Bordeaux vineyards,” he said. “Over the last 100+ years they have developed rich, complex characters, which are reflected in each wine. It’s taken me 40 years to find these vineyards, work with the owners to rejuvenate them, and create these wines which are the best of my career.”

The 2021 Barossa vintage has been tipped as the best in living memory. “I’ve waited more than four decades to be in the right place at the right time,” Powell jokes. “I feel extraordinarily privileged to have secured the very best grapes from some of the most exceptional vineyards in the Barossa. The climatic conditions that led up to this vintage will never be repeated – I think these wines may well be the best I ever make.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information and interviews with Dave Powell:
Kristin Westlake | kwestlake@thecontinuumpartners.com | +61 416 219 358

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye